Mounjaro vs Zepbound: Same Drug, Two Brands

Like their semaglutide counterparts, Mounjaro and Zepbound are the same medication (tirzepatide) sold under two names for two purposes: Mounjaro is approved for type 2 diabetes, and Zepbound is approved for weight management. The drug, the doses, and the effectiveness are identical; what differs is the approved use, the branding, and often the insurance coverage. If weight loss is your goal, Zepbound is the on-label version. Here’s the full picture.

One Molecule, Two Products

Eli Lilly developed tirzepatide and first launched it as Mounjaro for type 2 diabetes. Because it also produced remarkable weight loss (more than any previous approved drug at the time), Lilly pursued a separate obesity approval and branded that version Zepbound. It’s the exact same molecule at the same dose range, just approved and marketed for different conditions. This mirrors how Ozempic and Wegovy split the semaglutide market.

Head to Head

Same Drug, Same Results

Because Mounjaro and Zepbound are identical tirzepatide, their weight-loss effect is the same. Tirzepatide’s power was established in the SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, which showed up to about 21% weight loss. Whether that drug is labeled Mounjaro or Zepbound, the biology doesn’t change. Consider a hypothetical patient told they could take “Mounjaro for weight loss”: the effect would be identical to Zepbound, but Zepbound is the version actually approved and dosed for weight management, which matters for prescribing and coverage.

Why the Distinction Matters

If the drug is the same, why care which brand? A few practical reasons. Insurance often covers Mounjaro only for diabetes and Zepbound only for weight management, so the right brand affects whether your plan pays. Prescribing on-label (Zepbound for weight, Mounjaro for diabetes) is cleaner and avoids off-label complications. And Zepbound has picked up an additional approval for obstructive sleep apnea, slightly expanding its uses. So the brand you’re prescribed should match your condition.

Which Should You Use?

For weight management, Zepbound is the appropriate choice, approved and dosed for it. Mounjaro is the diabetes version. If you have both type 2 diabetes and obesity, a provider can determine which brand best fits your primary diagnosis and coverage. The good news is that either way, you’re getting the same highly effective drug.

What This Means for You Right Now

Both Mounjaro and Zepbound are available, and both are among the brand options TrimRx offers, alongside compounded tirzepatide. A provider can help you get the right tirzepatide product for your situation, whether the goal is weight loss, diabetes management, or both.

Frequently Asked Questions

Are Mounjaro and Zepbound the same drug?

Yes. Both are tirzepatide, at the same dose range, with the same effectiveness. They’re different brands approved for different uses: Mounjaro for type 2 diabetes, Zepbound for weight management.

Can I take Mounjaro for weight loss?

Mounjaro is the same drug as Zepbound, but it’s approved for diabetes, so using it for weight loss would be off-label. Zepbound is the version approved and dosed for weight management, which also affects insurance coverage.

Is one more effective than the other?

No. Since they’re the same drug at the same doses, their weight-loss effect is identical. The difference is the approved use, branding, and coverage, not effectiveness.

To find the right fit, you can check what you’re eligible for with a licensed provider.

This information is for educational purposes and is not medical advice. Consult a healthcare provider before starting any medication. Individual results may vary.